SE460356B - Modifierade skiktsilikatleror, saett foer deras framstaellning samt terapeutiska komposition innehaallande desamma - Google Patents
Modifierade skiktsilikatleror, saett foer deras framstaellning samt terapeutiska komposition innehaallande desammaInfo
- Publication number
- SE460356B SE460356B SE8302394A SE8302394A SE460356B SE 460356 B SE460356 B SE 460356B SE 8302394 A SE8302394 A SE 8302394A SE 8302394 A SE8302394 A SE 8302394A SE 460356 B SE460356 B SE 460356B
- Authority
- SE
- Sweden
- Prior art keywords
- clay
- magnesium hydroxide
- plate spacing
- parts
- heated
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 34
- 238000002360 preparation method Methods 0.000 title claims description 5
- 230000001225 therapeutic effect Effects 0.000 title claims description 4
- 239000004927 clay Substances 0.000 claims description 28
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 21
- 239000000347 magnesium hydroxide Substances 0.000 claims description 21
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 238000002083 X-ray spectrum Methods 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 238000005341 cation exchange Methods 0.000 claims 5
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 244000248349 Citrus limon Species 0.000 claims 1
- 235000005979 Citrus limon Nutrition 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- -1 magnesium nitroxide Chemical class 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 18
- 235000012254 magnesium hydroxide Nutrition 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- 239000011777 magnesium Substances 0.000 description 9
- 230000035484 reaction time Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000007858 starting material Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000010802 sludge Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001458 anti-acid effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NOOLISFMXDJSKH-ZDGBYWQASA-N (2s,5r)-5-methyl-2-propan-2-ylcyclohexan-1-ol Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1O NOOLISFMXDJSKH-ZDGBYWQASA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052599 brucite Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/20—Silicates
- C01B33/26—Aluminium-containing silicates, i.e. silico-aluminates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8212448 | 1982-04-29 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8302394D0 SE8302394D0 (sv) | 1983-04-28 |
| SE8302394L SE8302394L (sv) | 1983-10-30 |
| SE460356B true SE460356B (sv) | 1989-10-02 |
Family
ID=10530064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8302394A SE460356B (sv) | 1982-04-29 | 1983-04-28 | Modifierade skiktsilikatleror, saett foer deras framstaellning samt terapeutiska komposition innehaallande desamma |
Country Status (36)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69207656T2 (de) * | 1991-01-30 | 1996-10-17 | The Wellcome Foundation Ltd., London | Wasserlösliche tabletten |
| US7109257B2 (en) * | 2001-09-27 | 2006-09-19 | Rohm And Haas Company | Modified clays and methods for making and using same |
| FR2875405B1 (fr) * | 2004-09-17 | 2007-01-19 | Sod Conseils Rech Applic | Procede de purification d'une argile |
| DE102024121958A1 (de) | 2023-08-11 | 2025-02-13 | Devinochem GmbH & Co.KG | Schichtsilikat, Verfahren zu dessen Herstellung und dessen Verwendung |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE958021C (de) * | 1953-07-22 | 1957-02-14 | Degussa | Verfahren zur Herstellung feinteiliger Produkte mit grosser aktiver Oberflaeche aus natuerlichen Silicaten |
| GB834934A (en) * | 1956-09-26 | 1960-05-11 | Fuji Chem Ind Co Ltd | Process for the manufacture of magnesium alumino-silicate for medical uses |
| US3041238A (en) * | 1958-08-06 | 1962-06-26 | Minerals & Chem Philipp Corp | Method of preparing activated attapulgite |
| US3514268A (en) * | 1965-12-27 | 1970-05-26 | Fuji Chem Ind Co Ltd | Novel process for the manufacture of dimagnesium aluminosilicate for medical uses |
| US3690907A (en) * | 1970-05-20 | 1972-09-12 | Dow Chemical Co | Method of producing clay-base pigment |
| JPS5510539B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1972-05-22 | 1980-03-17 | ||
| US3855147A (en) * | 1972-05-26 | 1974-12-17 | Nl Industries Inc | Synthetic smectite compositions, their preparation, and their use as thickeners in aqueous systems |
| GB1537766A (en) * | 1976-03-31 | 1979-01-10 | Nl Industries Inc | Catalyst useful in alkylation of aromatic hydrocarbons |
| US4054537A (en) * | 1976-04-26 | 1977-10-18 | N L Industries, Inc. | Process for synthesizing compositions containing smectite-type clays and gellants produced thereby |
| US4040974A (en) * | 1976-04-26 | 1977-08-09 | N L Industries, Inc. | Synthesized gellants containing smectite-type clay and process for producing same |
| ZA781169B (en) * | 1978-03-03 | 1979-02-28 | Imperial College | Synthesis of clay-like materials |
| FR2435442A1 (fr) * | 1978-09-07 | 1980-04-04 | Om Lab Sa | Silicate de magnesium et d'aluminium synthetique, procede de fabrication de celui-ci et compositions pharmaceutiques comprenant celui-ci |
| JPS5715996A (en) * | 1980-07-03 | 1982-01-27 | Mizusawa Ind Chem Ltd | Novel clay mineral based color former for heat-sensitive copying paper and production thereof |
-
1983
- 1983-04-06 IL IL68311A patent/IL68311A0/xx not_active IP Right Cessation
- 1983-04-07 GR GR71029A patent/GR78823B/el unknown
- 1983-04-07 NZ NZ203810A patent/NZ203810A/en unknown
- 1983-04-08 IN IN237/DEL/83A patent/IN159147B/en unknown
- 1983-04-12 AR AR292683A patent/AR229204A1/es active
- 1983-04-12 BE BE0/210535A patent/BE896438A/fr not_active IP Right Cessation
- 1983-04-13 ZA ZA832604A patent/ZA832604B/xx unknown
- 1983-04-14 LU LU84750A patent/LU84750A1/fr unknown
- 1983-04-14 FI FI831254A patent/FI79945C/fi not_active IP Right Cessation
- 1983-04-15 FR FR8306158A patent/FR2525900B1/fr not_active Expired
- 1983-04-15 MA MA19994A patent/MA19774A1/fr unknown
- 1983-04-15 FR FR8306159A patent/FR2526004B1/fr not_active Expired
- 1983-04-19 CH CH2084/83A patent/CH657605A5/fr not_active IP Right Cessation
- 1983-04-19 NL NL8301368A patent/NL192974C/nl not_active IP Right Cessation
- 1983-04-22 JP JP58070185A patent/JPS58194816A/ja active Granted
- 1983-04-26 DZ DZ836832A patent/DZ534A1/fr active
- 1983-04-27 PT PT76603A patent/PT76603B/pt unknown
- 1983-04-27 EG EG263/83A patent/EG15949A/xx active
- 1983-04-28 MX MX008882A patent/MX168602B/es unknown
- 1983-04-28 DK DK190183A patent/DK161193C/da not_active IP Right Cessation
- 1983-04-28 HU HU831460A patent/HU190895B/hu not_active IP Right Cessation
- 1983-04-28 IE IE977/83A patent/IE54862B1/en not_active IP Right Cessation
- 1983-04-28 ES ES521903A patent/ES521903A0/es active Granted
- 1983-04-28 NO NO831502A patent/NO161795C/no not_active IP Right Cessation
- 1983-04-28 AU AU14010/83A patent/AU551986B2/en not_active Expired
- 1983-04-28 CA CA000426936A patent/CA1203177A/en not_active Expired
- 1983-04-28 SE SE8302394A patent/SE460356B/sv not_active IP Right Cessation
- 1983-04-28 PL PL1983241689A patent/PL139483B1/pl unknown
- 1983-04-29 IT IT20844/83A patent/IT1164203B/it active
- 1983-04-29 DE DE3315606A patent/DE3315606A1/de active Granted
- 1983-04-29 KR KR1019830001827A patent/KR870002160B1/ko not_active Expired
- 1983-04-29 OA OA57988A patent/OA07416A/xx unknown
- 1983-04-29 YU YU969/83A patent/YU43542B/xx unknown
-
1985
- 1985-07-24 SG SG556/85A patent/SG55685G/en unknown
- 1985-10-10 HK HK790/85A patent/HK79085A/xx not_active IP Right Cessation
-
1986
- 1986-12-30 MY MY444/86A patent/MY8600444A/xx unknown
-
1987
- 1987-04-10 US US07/037,236 patent/US4839173A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101340979A (zh) | 提纯蒙脱石的方法和提纯蒙脱石及其组合物 | |
| TW200831115A (en) | Manufacture process | |
| DE2332484A1 (de) | Lutschpastillen mit verzoegerter freigabe | |
| DE112013003596T5 (de) | Zusammensetzungen, umfassend vernetzte kationbindende Polymere und deren Verwendung | |
| HK1243321A1 (en) | Mixed metal compounds used as antacids | |
| KR20100057078A (ko) | 고인산혈증의 치료를 위한 혼합 금속 화합물 | |
| DE68914810T2 (de) | Vinylpyridinium vernetztes Polymer. | |
| PL117242B1 (en) | Method for manufacturing synthetic aluminium and magnesium silicatejuminija | |
| Waldron-Edward et al. | Studies on the inhibition of intestinal absorption of radioactive strontium: III. The effect of administration of sodium alginate in food and in drinking water | |
| US4968510A (en) | Method of treating arthritis | |
| SE460356B (sv) | Modifierade skiktsilikatleror, saett foer deras framstaellning samt terapeutiska komposition innehaallande desamma | |
| JP7362646B2 (ja) | 共結晶 | |
| CH636012A5 (en) | Pharmacologically acceptable bile acid sequestering agent composition and process for its preparation | |
| DE202010013541U1 (de) | Zeolith-haltige Zubereitungen enthaltend Clinoptilolith | |
| US6004546A (en) | Pharmaceutical composition containing bismuth-polyacrylic acid compounds | |
| JP2020200302A (ja) | 虚血性脳血管障害に伴う障害の予防又は治療剤 | |
| GB2119355A (en) | Modified clays | |
| EP0549794A1 (en) | Stock solution of sucralfate suspended in water and production thereof | |
| JPS6229526A (ja) | 高カルシウム尿症の治療及び予防剤 | |
| JPS5936890B2 (ja) | 制癌剤 | |
| KR20000075839A (ko) | 염기성 탄산 알루미늄 마그네슘, 그 제조방법 및 위산 치료를위한 약학조성물로서의 이용 | |
| EP0403199A2 (en) | Compounds | |
| US5069912A (en) | Method of treating spastic colitis | |
| KR20100094991A (ko) | 궤양 치료제 | |
| RU2021260C1 (ru) | Соли акриловой кислоты, проявляющие цитопротекторную и противоязвенную активность, и состав, обладающий цитопротекторной и противоязвенной активностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8302394-5 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |